# SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

> **NCT00798213** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 29 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute
- Lymphoblastic Leukemia, Acute

## Interventions

- **DRUG:** SCH 727965
- **DRUG:** Gemtuzumab ozogamicin

## Key facts

- **NCT ID:** NCT00798213
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2015-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00798213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00798213, "SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00798213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*